-
Adamas Pharmaceuticals Inc. (Emeryville, Calif.) said once-daily doses of oral ADS-5102 improved levodopa-induced dyskinesia in the Phase II/III EASED trial in patients with Parkinson's disease (PD). Specifically, once-…
Published on 6/18/2013
-
Two groups of academic researchers published data on Tuesday in the Annals of Internal Medicine from a pair of independent reviews analyzing the safety and efficacy of InFuse Bone Graft from Medtronic Inc. (NYSE:MDT), …
Published on 6/18/2013
-
Gilead Sciences Inc. (NASDAQ:GILD) reported interim data showing twice-daily oral idelalisib led to an overall response rate (ORR), the primary endpoint, of 53.6% in the Phase II Study 101-09 to treat refractory …
Published on 6/17/2013
-
Boehringer Ingelheim GmbH (Ingelheim, Germany) reported data from the Phase IIb SOUND-C3 trial evaluating an all-oral regimen that included the company's faldaprevir and deleobuvir to treat chronic HCV genotype 1 …
Published on 6/13/2013
-
Celltrion Inc. (KOSDAQ:068270) presented Phase I data comparing its CT-P13 with Remicade infliximab from Johnson & Johnson (NYSE:JNJ) and partner Merck & Co. Inc. (NYSE:MRK) at the European League Against Rheumatism …
Published on 6/13/2013
-
Early next year, Friends of Cancer Research plans to start a Phase II/III trial of three or four investigational compounds as second-line treatments for advanced, stage IIIB or stage IV squamous cell carcinoma of the …
Published on 6/13/2013
-
Eli Lilly and Co. (NYSE:LLY) discontinued the Phase II BACC trial evaluating once-daily oral LY2886721 for 26 weeks in patients with Alzheimer's disease (AD) after cases of abnormal liver biochemical tests were …
Published on 6/13/2013
-
Researchers at Emory University reported data from an open-label trial examining brain glucose metabolism in major depressive disorder (MDD) patients receiving generic escitalopram or cognitive behavior therapy (CBT) …
Published on 6/13/2013
-
Amgen Inc. (NASDAQ:AMGN) said once-weekly trebananib (AMG 386) plus paclitaxel met the primary endpoint of improving median progression-free survival (PFS) vs. placebo plus paclitaxel in the Phase III TRINOVA-1 trial to…
Published on 6/12/2013
-
Amgen Inc. (NASDAQ:AMGN) and AstraZeneca plc (LSE:AZN; NYSE:AZN) said subcutaneous brodalumab met the primary endpoint compared to placebo in a Phase II trial to treat psoriatic arthritis. Both 140 and 280 mg …
Published on 6/12/2013
-
Researchers at the Department of Veteran Affairs published a study that they said suggests a strategy of first administering a triple therapy of generics to treat adults with active rheumatoid arthritis (RA) before …
Published on 6/12/2013
-
Esperion Therapeutics Inc. (Plymouth, Mich.) said once-daily oral ETC-1002 met the primary endpoint of reducing mean LDL-C from baseline to week eight vs. placebo in a Phase IIa trial to treat hypercholesterolemia (32% …
Published on 6/7/2013
-
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) jumped $22.53 (10%) to $252.17 on Thursday after the company and partner Bayer AG (Xetra:BAYN) said intravitreal Eylea aflibercept met the primary endpoint in the Phase III …
Published on 6/6/2013
-
The Janssen R&D Ireland unit of Johnson & Johnson (NYSE:JNJ) presented data on Thursday at the Japan Society of Hepatology meeting in Tokyo from the four Japanese Phase III CONCERTO trials evaluating simeprevir (TMC435)…
Published on 6/6/2013
-
Shares of Pluristem Therapeutics Inc. (NASDAQ:PSTI; Tel Aviv:PSTI) slid on Tuesday after FDA placed a clinical hold on a U.S. Phase II trial of PLX-PAD -- allogeneic, placental-derived expanded (PLX) cells -- to treat …
Published on 6/4/2013
-
Eli Lilly and Co. (NYSE:LLY) said first-line treatment with Alimta pemetrexed plus carboplatin followed by Alimta as maintenance therapy missed the primary endpoint in the Phase III PRONOUNCE trial to treat advanced non…
Published on 6/3/2013
-
Researchers at Memorial Sloan-Kettering Cancer Center presented data at the American Society of Clinical Oncology meeting showing that oral selumetinib from Array BioPharma Inc. (NASDAQ:ARRY) met the primary endpoint of…
Published on 6/3/2013
-
The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) said Avastin bevacizumab plus temozolomide and radiation missed the co-primary endpoint of improving median overall survival (OS) vs. placebo plus temozolomide and…
Published on 6/3/2013
-
Boehringer Ingelheim GmbH (Ingelheim, Germany) said second-line treatment with twice-daily nintedanib plus docetaxel met the primary endpoint of improving median progression-free survival (PFS) vs. placebo plus …
Published on 6/3/2013
-
Celltrion Inc. (KOSDAQ:068270) presented pooled data for CT-P6, a biosimilar version of cancer drug Herceptin trastuzumab, at the American Society of Clinical Oncology meeting. In 475 patients with confirmed HER2-…
Published on 6/3/2013
-
Shares of Clovis Oncology Inc. (NASDAQ:CLVS) more than doubled on Monday after the company presented preliminary Phase I data for two cancer candidates at the American Society of Clinical Oncology meeting in Chicago. …
Published on 6/3/2013
-
GemVax & Kael Co. Ltd. (KOSDAQ:082270) said both concurrent and sequential administrations of GV1001 plus standard of care of gemcitabine and capecitabine missed the primary endpoint of improving overall survival (OS) …
Published on 6/3/2013
-
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) presented additional data from the Phase III AGO-OVAR16 trial evaluating Votrient pazopanib to treat ovarian, fallopian tube or primary peritoneal cancer at the American Society …
Published on 6/3/2013
-
Merck KGaA (Xetra:MRK) said first-line treatment with Erbitux cetuximab plus FOLFIRI chemotherapy missed the primary endpoint of significantly improving objective response rate (ORR) ORR vs. Avastin bevacizumab plus …
Published on 6/3/2013
-
Merck & Co. Inc. (NYSE:MRK) presented data at the American Society of Clinical Oncology meeting in Chicago showing that lambrolizumab (MK-3475) led to an objective response rate (ORR) of 38% in 117 evaluable patients …
Published on 6/3/2013